Natural Product (NP) Details
General Information of the NP (ID: NP3718) | |||||
---|---|---|---|---|---|
Name |
Honokiol
|
||||
Synonyms |
5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100; Honokiol,(S); UNII-11513CCO0N; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; 3',5-Diallylbiphenyl-2,4'-diol; CPD000387107; CHEMBL16901; CHEBI:5759; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; 11513CCO0N; 3',5-diallyl-2,4'-biphenyldiol; AK-25837; 5,3& -Diallyl-2,4& Q-100425; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; SMR000387107; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; houpa; 35354-74-6
Click to Show/Hide
|
||||
Species Origin | Magnolia officinalis ... | Click to Show/Hide | |||
Magnolia officinalis | |||||
Spiranthes bightensis | |||||
Disease | Pancreatic cancer [ICD-11: 2C10] | Investigative | [1] | ||
Structure |
Click to Download Mol2D MOL |
||||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
Formula |
C18H18O2
|
||||
PubChem CID | |||||
Canonical SMILES |
C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C
|
||||
InChI |
1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2
|
||||
InChIKey |
FVYXIJYOAGAUQK-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 35354-74-6
|
||||
Herb ID | |||||
ETMC ID | |||||
SymMap ID | |||||
TCMSP ID | |||||
TTD Drug ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
Temozolomide | Brain cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | CASP3 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
GL261 | CVCL_Y003 | Mouse glioblastoma | Mus musculus | |||
Experimental
Result(s) |
Honokiol enhanced temozolomide-induced autophagy and apoptosis in drug-sensitive and -tolerant glioma cells. | |||||
Oxaliplatin | Colorectal cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | AKT1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | ERK1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | ERK2 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | RELA | Molecule Info |
Pathway MAP
|
||
In-vitro Model | HT-29 | CVCL_0320 | Colon adenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Honokiol augments the anti-cancer effects of oxaliplatin in colon cancer cells. | |||||
Bleomycin | Hodgkin lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [4] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Activity | POLB | Molecule Info |
Pathway MAP
|
|
Down-regulation | Activity | POLL | Molecule Info |
Pathway MAP
|
||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
PANC-1 | CVCL_0480 | Pancreatic ductal adenocarcinoma | Homo sapiens | |||
UACC-903 | CVCL_4052 | Cutaneous melanoma | Homo sapiens | |||
Experimental
Result(s) |
Honokiol inhibits DNA polymerases Beta and Lambda and increases Bleomycin sensitivity of human cancer cells. | |||||
Chloroquine | Malaria | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | MAP1LC3A | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | SQSTM1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | NCI-H460 | CVCL_0459 | Lung large cell carcinoma | Homo sapiens | ||
A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Honokiol exhibits enhanced antitumor effects with chloroquine by inducing cell death and inhibiting autophagy in human non-small cell lung cancer cells. | |||||
Rapamycin | Multiple myeloma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | PD-L1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | 786-O | CVCL_1051 | Renal cell carcinoma | Homo sapiens | ||
ACHN | CVCL_1067 | Papillary renal cell carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Honokiol can effectively overcome the limitation of Rapamycin treatment alone, and the combination treatment can markedly restrict the growth of RCC, with particular importance to post-transplantation renal cancer. | |||||
Rosiglitazone | Prostate cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | CCND1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | CCNE1 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | CDKN1A | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | RB1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | Mahlavu | CVCL_0405 | Hepatocellular carcinoma | Homo sapiens | ||
SK-HEP-1 | CVCL_0525 | Hepatocellular carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Honokiol combined with rosiglitazone showed more effective growth inhibition in hepatoma cells mediated through the regulation of G0/G1 phase-related proteins p21, cyclin D1, cyclin E1, and Rb and cell cycle progression. | |||||
5-fluorouracil | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | BCL-2 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Phosphorylation | EGFR | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
In-vitro Model | HSC-3 | CVCL_1288 | Tongue squamous cell carcinoma | Homo sapiens | ||
HSC-4 | CVCL_1289 | Tongue squamous cell carcinoma | Homo sapiens | |||
In-vivo Model | A total of 2*106 HSC-3 cells were suspended in 100 uL serum-free DMEM and injected subcutaneously into the right flank of BALB/c nude mice to establish OSCC xenograft models. | |||||
Experimental
Result(s) |
HNK and 5-FU exert a synergistic therapeutic effect on OSCC by inducing apoptosis. | |||||
Gemcitabine | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [9] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Phosphorylation | NFKBIA | Molecule Info |
Pathway MAP
|
|
Experimental
Result(s) |
Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. | |||||
Cisplatin | Bladder cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [10] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | SK-OV-3 | CVCL_0532 | Ovarian serous cystadenocarcinoma | Homo sapiens | ||
Experimental
Result(s) |
Combining liposomal honokiol with cisplatin enhances therapeutic effectiveness in ovarian carcinoma. | |||||
Imatinib | Mantle cell lymphoma | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [11] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | NB4 | CVCL_0005 | Acute promyelocytic leukemia | Homo sapiens | ||
K-562 | CVCL_0004 | Chronic myelogenous leukemia | Homo sapiens | |||
Experimental
Result(s) |
Honokiol induces paraptosis and apoptosis and exhibits schedule-dependent synergy in combination with imatinib in human leukemia cells. | |||||
X-ray irradiation | Scaphoid Fracture | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [12] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | A-549 | CVCL_0023 | Lung adenocarcinoma | Homo sapiens | ||
NCI-H1299 | CVCL_0060 | Lung large cell carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Honokiol demonstrated low cytotoxicity to NSCLC cells and a pronounced radiosensitizing effect on NSCLC cells exposed to carbon ions than X-rays. | |||||
Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [13] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
In-vitro Model | 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | ||
BCaP-37 | CVCL_0164 | Breast cancer | Homo sapiens | |||
MCF-7 | CVCL_0031 | Invasive breast carcinoma | Homo sapiens | |||
In-vivo Model | Mouse 4T1 breast cancer cells (1.0*105) were suspended in 0.1 mL of normal saline (NS) and injected subcutaneously in theright axillary fossa of BALB/c mice. | |||||
Experimental
Result(s) |
Honokiol inhibited the proliferation of 4T1 cells via apoptosis and significantly enhanced the apoptosis of 4T1 cells induced by adriamycin. | |||||
β. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
Celecoxib | Rheumatoid arthritis | Click to Show/Hide the Molecular Data of This Drug | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [14] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | FOXM1 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | FOXP3 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | ITGAM | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | MKI67 | Molecule Info | |||
Down-regulation | Expression | NNT | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | PECAM1 | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | VEGFA | Molecule Info |
Pathway MAP
|
||
In-vitro Model | 4T1 | CVCL_0125 | Malignant neoplasms | Mus musculus | ||
Experimental
Result(s) |
The combined treatment with PV-CXB and PV-HNK showed synergistic effect both in vitro and in vivo. | |||||
γ. A List of Drug(s) Whose Resistance can be Reversed by This NP | ||||||
Osimertinib | Lung cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
Reversing Drug Resistance | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [15] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Molecule(s)
Regulation |
Down-regulation | Expression | MCL1 | Molecule Info |
Pathway MAP
|
|
In-vitro Model | PC-9 | CVCL_B260 | Lung adenocarcinoma | Homo sapiens | ||
HCC827 | CVCL_2063 | Lung adenocarcinoma | Homo sapiens | |||
Experimental
Result(s) |
Overcoming acquired resistance of EGFR-mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Arachidonate 5-lipoxygenase (5-LOX) | Molecule Info | [16] | |
Prostaglandin-endoperoxide synthas (COX) | Molecule Info | [16] | ||
BioCyc | Aspirin-triggered lipoxin biosynthesis | Click to Show/Hide | ||
2 | Resolvin D biosynthesis | |||
3 | Leukotriene biosynthesis | |||
4 | Lipoxin biosynthesis | |||
5 | Aspirin triggered resolvin D biosynthesis | |||
6 | Aspirin triggered resolvin E biosynthesis | |||
KEGG Pathway | Arachidonic acid metabolism | Click to Show/Hide | ||
2 | Metabolic pathways | |||
3 | Serotonergic synapse | |||
4 | Ovarian steroidogenesis | |||
5 | Toxoplasmosis | |||
NetPath Pathway | IL4 Signaling Pathway | Click to Show/Hide | ||
Pathwhiz Pathway | Arachidonic Acid Metabolism | Click to Show/Hide | ||
WikiPathways | Vitamin D Receptor Pathway | Click to Show/Hide | ||
2 | Arachidonic acid metabolism | |||
3 | Eicosanoid Synthesis | |||
4 | Selenium Micronutrient Network |